Sex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center Experience

被引:18
作者
Grupper, Avishay [1 ]
Nestorovic, Emilija M. [2 ]
Daly, Richard C. [1 ]
Milic, Natasa M. [3 ]
Joyce, Lyle D. [1 ]
Stulak, John M. [1 ]
Joyce, David L. [1 ]
Edwards, Brooks S. [1 ]
Pereira, Naveen L. [1 ]
Kushwaha, Sudhir S. [1 ]
机构
[1] Mayo Clin, Div Cardiovasc Dis & Cardiovasc Surg, Rochester, MN USA
[2] Hosp Cardiac Surg, Clin Ctr Serbia, Belgrade, Serbia
[3] Univ Belgrade, Fac Med, Inst Med Stat & Informat, Belgrade, Serbia
来源
TRANSPLANTATION DIRECT | 2016年 / 2卷 / 10期
关键词
D O I
10.1097/TXD.0000000000000616
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Pregnancies may result in antibodies against HLA, a risk factor for antibody-mediated rejection (AMR) and subsequent cardiac allograft vasculopathy (CAV) after heart transplantation (HTx). The aim of this study was to evaluate sex differences in the incidence of AMR events and subsequent risk of CAV among HTx recipients. Methods. The study comprised 160 patients (51 [32%] women) who underwent HTx in 2008 to 2014. The cumulative effect of AMR events was calculated by AMR score (sum of myocardial biopsy grading divided by number of biopsies taken during 3 years post-HTx). Results. Females had higher levels of anti-HLA I antibodies pre-HTx compared to males which was associated with a history of pregnancies, total number of children and with a higher AMR score at 6 months post-HTx (P < 0.05). Women demonstrated a significant increase in the total incidence of AMR events (27 vs. 7%, P = 0.001) and in AMR scores at 6, 12, 24 and 36 months post-HTx compared to men (P < 0.05). There were no differences in cellular rejection between the groups. A history of AMR events was associated with a significantly increased risk of severe CAV onset (hazard ratio, 7.0; 95% confidence interval, 1.5-31.5; P = 0.012). Conclusions. Women are at higher risk for AMR post-HTx which subsequently increases their risk for CAV. Females recipients may benefit from closer surveillance to identify AMR at an earlier stage post-HTx, and targeted immunosuppressive therapy to attenuate the development of CAV.
引用
收藏
页数:6
相关论文
共 27 条
  • [1] Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy
    Bae, Jang-Ho
    Rihal, Charanjit S.
    Edwards, Brooks S.
    Kushwaha, Sudhir S.
    Mathew, Verghese
    Prasad, Abhiram
    Holmes, David R., Jr.
    Lerman, Amir
    [J]. TRANSPLANTATION, 2006, 82 (08) : 1108 - 1111
  • [2] The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011)
    Berry, Gerald J.
    Angelini, Annalisa
    Burke, Margaret M.
    Bruneval, Patrick
    Fishbein, Michael C.
    Hammond, Elizabeth
    Miller, Dylan
    Neil, Desley
    Revelo, Monica P.
    Rodriguez, E. Rene
    Stewart, Susan
    Tan, Carmela D.
    Winters, Gayle L.
    Kobashigawa, Jon
    Mehra, Mandeep R.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (06) : 601 - 611
  • [3] Gender-Based Analysis of Outcome After Heart Transplantation
    Eifert, Sandra
    Kofler, Sieglinde
    Nickel, Thomas
    Horster, Sophia
    Bigdeli, Amir Khosrow
    Beiras-Fernandez, Andres
    Meiser, Bruno
    Kaczmarek, Ingo
    [J]. EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2012, 10 (04) : 368 - 374
  • [4] Immunologic effects of implantation of left ventricular assist devices
    Erren, M
    Schlüter, B
    Fobker, M
    Plenz, G
    Baba, H
    Willeke, P
    Kwiotek, R
    Junker, R
    Assmann, G
    Scheld, HH
    Deng, MC
    [J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1965 - 1968
  • [5] Effect of Pretransplant Human Leukocyte Antigen Antibodies Detected by Solid-Phase Assay on Heart Transplant Outcomes
    Gandhi, M. J.
    DeGoey, S. R.
    Bundy, K.
    Kremers, W. K.
    Knauer, R.
    Pereira, N.
    Edwards, B.
    Kushwaha, S.
    Daly, R. C.
    [J]. TRANSPLANTATION PROCEEDINGS, 2011, 43 (10) : 3840 - 3846
  • [6] Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years - A randomized clinical trial
    Keogh, A
    Richardson, M
    Ruygrok, P
    Spratt, P
    Galbraith, A
    O'Driscoll, G
    Macdonald, P
    Esmore, D
    Muller, D
    Faddy, S
    [J]. CIRCULATION, 2004, 110 (17) : 2694 - 2700
  • [7] Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: Defining rejection patterns
    Kfoury, Abdallah G.
    Stehlik, Josef
    Renlund, Dale G.
    Snow, Gregory
    Seaman, James T.
    Gilbert, Edward M.
    Stringham, James S.
    Long, James W.
    Hammond, M. Elizabeth H.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (11) : 1277 - 1282
  • [8] Kobashigawa JA, 1996, CIRCULATION, V94, P294
  • [9] Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after head transplantation
    Matsuo, Yoshiki
    Cassar, Andrew
    Yoshino, Satoshi
    Flammer, Andreas J.
    Li, Jing
    Gulati, Rajiv
    Topilsky, Yan
    Raichlin, Eugenia
    Lennon, Ryan J.
    Lerman, Lilach O.
    Rihal, Charanjit S.
    Kushwaha, Sudhir S.
    Lerman, Amir
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (08) : 784 - 791
  • [10] HLA alloimmunization in patients requiring ventricular assist device support
    McKenna, DH
    Eastlund, T
    Segall, M
    Noreen, HJ
    Park, S
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (11) : 1218 - 1224